Tetrachlorodecaoxide

Tetrachlorodecaoxide
Clinical data
ATC code	D03AX11 (WHO) ;
Identifiers
	IUPAC name Molecular oxygen tetrachlorite hydrate;
CAS Number	92047-76-2 ;
PubChem CID	3000391;
UNII	549BT7IE1Q;
CompTox Dashboard (EPA)	DTXSID40238840 ;
ECHA InfoCard	100.101.959
(verify)

Tetrachlorodecaoxide (TCDO) is a chlorite-containing, immunomodulatory, macrophage-activating drug whose chemical formula is Cl₄H₂O₁₁.[1][2][3] The drug WF10 (Macrokine, Immunokine) is an aqueous solution of tetrachlorodecaoxide designed for intravenous injection.[2] Tetrachlorodecaoxide and WF10 were originally developed by Oxo Chemie.[4]

Tetrachlorodecaoxide / WF10 is used in the management of radiation cystitis,[5] is effective in the treatment of diabetic foot ulcers,[6] and is used in wound healing, where the mechanism of action is activation of the macrophage system, and increasing the partial pressure of oxygen in the wound.[7]

References

"Tetrachlorodecaoxide - Cl4H2O11-4". Pubchem.ncbi.nlm.mih.gov. Retrieved 2016-12-20.
"WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.
Maraprygsavan, Paiboon; Mongkolsuk, Jarasporn; Arnhold, Juergen; Kuehne, Friedrich-Wilhelm (2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–8. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.
"About Us - Immunokine® - WF10 - OXO Chemie (Thailand) Co., Ltd". Oxothai.com. Retrieved 2016-12-20.
Smit, Shaun G.; Heyns, Chris F. (2010). "Management of radiation cystitis" (PDF). Nature Reviews Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. PMID 20212517.
Yingsakmongkol, N. (2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.
Parikh, Romil; Bakhshi, Girish; Naik, Madhushree; Gaikwad, Bhargav; Jadhav, Kavita; Tayade, Mukund (2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.

External links

Tetrachlorodecaoxide in the ChemIDplus database
Tetrachlorodecaoxide at Bionity.com
Tetrachlorodecaoxide at Drugs.com
Tetrachlorodecaoxide at Wikidoc.org

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Tetrachlorodecaoxide - Cl4H2O11-4". Pubchem.ncbi.nlm.mih.gov. Retrieved 2016-12-20.

[informa.com-2] "WF10". Drugprofiles.informa.com. Retrieved 2016-12-20.

[3] Maraprygsavan, Paiboon; Mongkolsuk, Jarasporn; Arnhold, Juergen; Kuehne, Friedrich-Wilhelm (2016). "The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome". Journal of Clinical & Translational Endocrinology. 4: 53–8. doi:10.1016/j.jcte.2016.05.001. PMC 5680448. PMID 29159131.

[4] "About Us - Immunokine® - WF10 - OXO Chemie (Thailand) Co., Ltd". Oxothai.com. Retrieved 2016-12-20.

[5] Smit, Shaun G.; Heyns, Chris F. (2010). "Management of radiation cystitis" (PDF). Nature Reviews Urology. 7 (4): 206–14. doi:10.1038/nrurol.2010.23. PMID 20212517.

[6] Yingsakmongkol, N. (2013). "Clinical outcomes of WF10 adjunct to standard treatment of diabetic foot ulcers". Journal of Wound Care. 22 (3): 130–2, 134–6. doi:10.12968/jowc.2013.22.3.130. PMID 23665731.

[7] Parikh, Romil; Bakhshi, Girish; Naik, Madhushree; Gaikwad, Bhargav; Jadhav, Kavita; Tayade, Mukund (2016). "The Efficacy and Safety of Tetrachlorodecaoxide in Comparison with Super-oxidised Solution in Wound Healing". Archives of Plastic Surgery. 43 (5): 395–401. doi:10.5999/aps.2016.43.5.395. PMC 5040840. PMID 27689045.